Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 11
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Vaccine Treatment for Hormone Refractory Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
19 and over
Pharmaceutical / Industry
NLG0103
398-04FB, NCT00105053
2.
Vaccine Treatment for Advanced Malignant Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
NLG0104
OBA#0404-640, NCT00300612
Last Modified:
4/20/2007
3.
Phase II Study of Active Intralymphatic Immunotherapy With Interferon Alfa-Treated Allogeneic Tumor Cells Plus Sargramostim (GM-CSF) and Cyclophosphamide in Patients With Advanced Pancreatic Adenocarcinoma (Summary Last Modified 06/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Other
SVMC-ONC-222P
NCI-V96-0886, NCT00002773
Last Modified:
12/20/2007
4.
Phase II Pilot Study of Cyclophosphamide and Active Intralymphatic Immunotherapy With a Vaccine Containing Interferon alfa or Interferon gamma-Treated Tumor Cells Followed By Sargramostim (GM-CSF) in Patients With Advanced Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Other
SVMC-ONC-222
NCI-V91-0075, NCT00002475
Last Modified:
7/23/2007
 
First Published:
1/24/2005
5.
Phase II Study of Adjuvant Vaccine Therapy Comprising Autologous Dendritic Cells Loaded With Allogeneic Non-small Cell Lung Cancer (NSCLC) Cells in Patients With Unresectable Stage IIIA or IIIB, or Resected Stage I-IIIB NSCLC
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 to 80
NCI, Other
UKMC-IRB-0391-F2R
UKMC-CTRF-G-01-009, NCT00103116
Last Modified:
12/27/2008
6.
Immunotherapy with BCG with or without Irradiated Allogeneic Cells for Stage I Lung Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Closed
no age specified
NCI-LUN-1
Last Modified:
12/27/2008
7.
Allogeneic Tumor Cells During Intensive Maintenance Chemotherapy After Induction with ARA-C/ADR for Acute Myelocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Closed
Under 70
RPMI-DMA-970701
NCI-D78-026-209
Last Modified:
12/28/2008
8.
Surgical Resection, Chemotherapy with CTX/ADR, Radiotherapy and Immunotherapy with BCG and Tumor Cells for Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Closed
under 18
SJCRH-NB-1
SJCRH-NB-74
Last Modified:
12/28/2008
9.
Chemotherapy plus BCG Immunotherapy with or without Allogeneic Tumor Cells for Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Closed
no age specified
SWE-LGMS-AML-1
Last Modified:
12/28/2008
10.
Chemotherapy with Adriamycin/Cyclophosphamide with or without BCG/Tumor Cell Vaccine Immunotherapy for Lung Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Closed
no age specified
UARIZ-IIIB
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute